The Congressional Dietary Supplement Caucus hosted an educational briefing and luncheon for congressional staffers on Oct. 14, the day before the 20th anniversary of the passage of the Dietary Supplement Health and Education Act.
Could the regulatory and scientific logjam that’s keeping copycat biotech medicines off the market and out of the hands of patients and health providers in the United States finally be breaking?
What’s in a name? A lot, apparently, if the name applies to a biosimilar medicine.
The U.S. Supreme Court on Wednesday heard arguments from Teva Pharmaceutical Industries in defense of the patent protecting its $4 billion multiple sclerosis drug Copaxone, according to a Reuters report.
U.S. Sen. Bernie Sanders, I-Vt., and U.S. Rep. Elijah Cummings, D-Md., earlier this month launched an investigation into soaring generic drug prices.
Twenty African-American and Hispanic community and health care organizations earlier this month submitted a letter to the Food and Drug Administration raising concerns that its Proposed Rule on Generic Labeling could jeopardize patient safety and access to affordable medicines.
Adults in the United States suffered from approximately 14 million major medical conditions attributable to smoking, according to a study published in the journal JAMA Internal Medicine Monday.
The Food and Drug Administration on Friday approved Gilead's Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus genotype 1 infection.
The Food and Drug Administration on Friday approved Akynzeo (netupitant and palonosetron) for the treatment of nausea and vomiting in patients who are undergoing cancer chemotherapy.
The Consumer Electronics Association on Thursday released a new study of adult Americans with hearing loss, finding that only 1-in-25 of those surveyed now own personal sound amplification products, and nearly 40% are interested in over-the-counter products to help them hear better.